References
1.Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N
Engl J Med. 1999 Sep 16;341(12):910-1. doi: 10.1056/NEJM199909163411209.
PMID: 10486424
2.Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer
DE. Prevalence of diagnosed atrial fibrillation in adults: national
implications for rhythm management and stroke prevention: the
Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.
JAMA. 2001;285:2370–2375. doi: 10.1001/jama.285.18.2370
3.Walters, T. E., Wick, K., Tan, G., Mearns, M., Joseph, S. A., Morton,
J. B., … & Kalman, J. M. (2018). Psychological distress and suicidal
ideation in patients with atrial fibrillation: prevalence and response
to management strategy. Journal of the American Heart Association,
7(18), e005502.
4.Calkins H, Kuck KH, Cappato R, et al. HRS/EHRA/ECAS expertconsensus
statement on catheter and surgical ablation of atrialfibrillation:
recommendations for patient selection, proceduraltechniques, patient
management and follow‐up, definitions, end-points, and research trial
design: a report of the heart rhythm society(HRS) task force on catheter
and surgical ablation of atrial fibrillation.Developed in partnership
with the European Heart Rhythm Associa-tion (EHRA), a registered branch
of the European Society ofCardiology (ESC) and the European Cardiac
Arrhythmia Society(ECAS); and in collaboration with the American College
of Cardiology(ACC), American Heart Association (AHA), the Asia Pacific
HeartRhythm Society (APHRS), and the society of thoracic surgeons
(STS).Endorsed by the governing bodies of the American College
ofCardiology Foundation, the American Heart Association, the Eur-opean
Cardiac Arrhythmia Society, the European Heart RhythmAssociation, the
Society of Thoracic Surgeons, the Asia Pacific HeartRhythm Society, and
the heart rhythm society.Heart Rhythm.2012;2012(9):632‐696. e621.6.
5.Prabhu, S., Taylor, A. J., Costello, B. T., Kaye, D. M., McLellan, A.
J., Voskoboinik, A., … & Kistler, P. M. (2017). Catheter ablation
versus medical rate control in atrial fibrillation and systolic
dysfunction: the CAMERA-MRI study. Journal of the American College of
Cardiology, 70(16), 1949-1961.
6.Marrouche, N. F., Brachmann, J., & CASTLE‐AF Steering Committee.
(2009). Catheter ablation versus standard conventional treatment in
patients with left ventricular dysfunction and atrial fibrillation
(castle‐af)‐study design. Pacing and clinical electrophysiology, 32(8),
987-994.
7.Miyazaki S, Kuwahara T, Kobori A, Takahashi Y, Takei A, Sato A, et al.
Pharmacological cardioversion preceding left atrial ablation: bepridil
predicts the clinical outcome following ablation in patients with
persistent atrial fibrillation. Europace. 2009;11:1620–3.
8.Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Arimoto T, Kuroki K, et
al. Effect of restoration of sinus rhythm by extensive anti-arrhythmic
drugs in predicting results of catheter ablation of persis- tent atrial
fibrillation. Am J Cardiol. 2010;106(1):62–8.
9.Benák, A., Kohári, M., Herczeg, A. et al. Selecting persistent atrial
fibrillation patients for pulmonary vein isolation based on the response
to amiodarone: efficacy of the “one step back” strategy. J Interv Card
Electrophysiol 56, 291–297 (2019).
https://doi.org/10.1007/s10840-019-00524-z
10. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus
T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B. Amiodarone to
prevent recurrence of atrial fibrillation. Canadian Trial of Atrial
Fibrillation Investigators. N Engl J Med. 2000 Mar 30;342(13):913-20.
doi: 10.1056/NEJM200003303421302. PMID: 10738049.
11. Kang JH, Lee DI, Kim S, Kim MN, Park YM, Ban JE, Choi JI, Lim HE,
Park SW, Kim YH. Prediction of long-term outcomes of catheter ablation
of persistent atrial fibrillation by parameters of preablation DC
cardioversion. J Cardiovasc Electrophysiol. 2012 Nov;23(11):1165-70.
doi: 10.1111/j.1540-8167.2012.02339.x. Epub 2012 Aug 8. PMID: 22882453.
12. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of
anti-arrhythmic drugs on fibrillation in the remodeled atrium: insights
into the mechanism of the superior efficacy of amiodarone. Circulation.
2003;107(10):1440–6.
13. Ashikaga K, Kobayashi T, Kimura M, Owada S, Sasaki S, Iwasa A, et
al. Effects of amiodarone on electrical and structural remodeling
induced in a canine rapid pacing-induced persistent atrial fibrilla-
tion model. Eur J Pharmacol. 2006;536(1–2):148–53.
14Slotwiner D, Steinberg J. Limited Ablation for Persistent Atrial
Fibrillation Using Preprocedure Reverse Remodelling. Arrhythm
Electrophysiol Rev. 2014 Aug;3(2):101-6. doi: 10.15420/aer.2014.3.2.101.
Epub 2014 Aug 30. PMID: 26835074; PMCID: PMC4711510.
15. Rivard L, Hocini M, Rostock T, Cauchemez B, Forclaz A, Jadidi AS,
Linton N, Nault I, Miyazaki S, Liu X, Xhaet O, Shah A, Sacher F, Derval
N, Jaïs P, Khairy P, Macle L, Nattel S, Willems S, Haïssaguerre M.
Improved outcome following restoration of sinus rhythm prior to catheter
ablation of persistent atrial fibrillation: a comparative multicenter
study. Heart Rhythm. 2012 Jul;9(7):1025-30. doi:
10.1016/j.hrthm.2012.02.016. Epub 2012 Feb 15. PMID: 22342863.
16.Yosuke Miwa, Hitoshi Minamiguchi, Anil K. Bhandari, David S. Cannom,
Ivan C. Ho, Amiodarone reduces the amount of ablation during catheter
ablation for persistent atrial fibrillation, EP Europace, Volume 16,
Issue 7, July 2014, Pages 1007–1014,
17. Verma A, Mantovan R, Macle L, De Martino G, Chen J, Morillo CA,
Novak P, Calzolari V, Guerra PG, Nair G, Torrecilla EG, Khaykin Y.
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation
(STAR AF): a randomized, multicentre, international trial. Eur Heart J.
2010 Jun;31(11):1344-56. doi: 10.1093/eurheartj/ehq041. Epub 2010 Mar 9.
PMID: 20215126; PMCID: PMC2878965.